THE INDIAN PHARMACIST Official Circular Pharmacy Logo THE INDIAN PHARMACISTLearn. Explore. Practise. Excel.
MEDICINE MONOGRAPH CODE: [11.28] ID: TIP-MED-000457 ⚠️ HIGH-ALERT / SPECIALIST SUPERVISION

Sumatriptan, Rizatriptan & Betahistine / Cinnarizine / Flunarizine

Active Ingredient / Scientific Identity: Sumatriptan, Rizatriptan & Betahistine / Cinnarizine / Flunarizine • Class: 5-HT1B/1D Receptor Agonist Acute Migraine Triptans & Vestibular/Migraine Prophylaxis Agents (Schedule H | NLEM 2022 [Sumatriptan, Betahistine, Flunarizine])

⚖️ Compare Profile
Generic / Entity NameSumatriptan, Rizatriptan & Betahistine / Cinnarizine / Flunarizine ([11.28])
Verified Indian Brands / RefGeneric Compendial Entry (No Commercial Brand Claimed)
Pharmacological Class5-HT1B/1D Receptor Agonist Acute Migraine Triptans & Vestibular/Migraine Prophylaxis Agent
Available Dosage FormsStandard hospital formulary strengths
Regulatory ClassificationNon-Schedule / OTC Pharmacist-Assisted Counselling
Key Warning & Review DateHigh-alert hospital specialist agent; administer under close physiological and laboratory monitoring.
Reviewed: 2026-11-10
Safety Matrix:⚖️ Legal Status: Non-Schedule / OTC Pharmacist-Assisted Counselling🚨 Clinically High-Alert: Independent Dose & Route Verification Required👨‍⚕️ Specialist-Supervised Therapy

1. Clinical & Scientific Overview

Sumatriptan, Rizatriptan & Betahistine / Cinnarizine / Flunarizine (TIP-MED-000457, Reference Code [11.28]) is classified under Neurology Medicines as a 5-HT1B/1D Receptor Agonist Acute Migraine Triptans & Vestibular/Migraine Prophylaxis Agents (Schedule H | NLEM 2022 [Sumatriptan, Betahistine, Flunarizine]). Within the Indian regulatory and compendial framework, it is governed under Non-Schedule / OTC Pharmacist-Assisted Counselling.

Verified Indian Market Examples / Compendial Status:
Representative Indian Formulations (for identification only): Sumatriptan: Suminat (Sun — 25, 50, 100 mg); FDC: Headset (Sumatriptan 85 mg + Naproxen 500 mg). Rizatriptan: Rizact / Rizact MD (Cipla — 5 mg, 10 mg). | Strengths: Sumatriptan Tablets: 25 mg, 50 mg, 100 mg; Nasal Spray: 20 mg; SC: 6 mg. Rizatriptan Tablets/MD: 5 mg, 10 mg. Betahistine Tablets: 8 mg, 16 mg, 24 mg, 48 mg SR. Cinnarizine Tablets: 25 mg, 75 mg. Flunarizine Tablets: 5 mg, 10 mg
Representative Indian Formulations (for identification only): Sumatriptan: Suminat (Sun — 25, 50, 100 mg); FDC: Headset (Sumatriptan 85 mg + Naproxen 500 mg). Rizatriptan: Rizact / Rizact MD (Cipla — 5 mg, 10 mg). | Strengths: Sumatriptan Tablets: 25 mg, 50 mg, 100 mg; Nasal Spray: 20 mg; SC: 6 mg. Rizatriptan Tablets/MD: 5 mg, 10 mg. Betahistine Tablets: 8 mg, 16 mg, 24 mg, 48 mg SR. Cinnarizine Tablets: 25 mg, 75 mg. Flunarizine Tablets: 5 mg, 10 mg
Dosage Forms & Available Strengths:
Standard hospital formulary strengths
Routes: Intravenous / Parenteral / Oral

3. Mechanism of Action & Pharmacodynamics

Established pharmacological class action (5-HT1B/1D Receptor Agonist Acute Migraine Triptans & Vestibular/Migraine Prophylaxis Agents (Schedule H | NLEM 2022 [Sumatriptan, Betahistine, Flunarizine])): targets primary receptor, enzyme, ion-channel, or cellular pathway to achieve therapeutic efficacy in Sumatriptan & Rizatriptan: **Acute abortive treatment of moderate-to-severe Migraine** attacks (with or without aura — NEVER for daily prophylaxis!).

4. Therapeutic Indications & Evidence-Supported Uses

  • Sumatriptan & Rizatriptan: **Acute abortive treatment of moderate-to-severe Migraine** attacks (with or without aura — NEVER for daily prophylaxis!)
  • Betahistine: Ménière's disease (vertigo, tinnitus, aural fullness — H3 antagonist / H1 agonist that improves cochlear stria vascularis blood flow without central sedation

🇮🇳 Jurisdiction & Indication Note: Indications and schedules reflect Indian compendial and regulatory records (CDSCO / Indian Pharmacopoeia & NFI / NLEM 2022). Where international reference labels (US FDA DailyMed / NCBI StatPearls) are cited for pharmacokinetic or mechanistic parameters, international approvals do not automatically imply CDSCO approval in India.

5. Educational Dosage Context, Formulations & Administration

Educational Dosing & Regimen Summary: Sumatriptan: 50–100 mg PO at onset of migraine headache; if headache recurs after initial relief, may repeat once after >=2 hours (Max 200 mg/24h). Rizatriptan: 5–10 mg PO/MD at onset; may repeat after >=2 hours (Max 20–30 mg/24h; **MAX 5 mg per dose [15 mg/24h] if patient is taking Propranolol!**). (Duration: Triptans: Acute episode only. Cinnarizine: Short-term <=1–2 weeks. Flunarizine: Limit to **<=2–3 months** (or use 5-days-on / 2-days-off regimen;)

Administration & Meal Timing: Oral (PO), Parenteral (IV / IM / SC as specified), Local Ophthalmic / ENT / Intranasal | Food & Meal Timing: Take Triptans as early as possible at the onset of the migraine headache phase (do NOT take during the visual aura phase before headache starts, as triptans are less effective during aura!). | Best Time of Day: Triptans: PRN at Migraine Onset (LIMIT to **<=2 days/week [<10 days/month]** to prevent Medication-Overuse Headache [MOH]!). Flunarizine: Bedtime (OD).

6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment

Absorption & Disposition:
Hospital pharmacokinetic profile; monitor therapeutic response and organ clearance.
Metabolism & Biotransformation:
Renal & Hepatic: Triptans are contraindicated in severe hepatic impairment; reduce Rizatriptan to 5 mg in severe CKD
Elimination & Renal Adjustment:
Renal & Hepatic: Triptans are contraindicated in severe hepatic impairment; reduce Rizatriptan to 5 mg in severe CKD
Hepatic Impairment Considerations:
Renal & Hepatic: Triptans are contraindicated in severe hepatic impairment; reduce Rizatriptan to 5 mg in severe CKD

7. Contraindications, Precautions & High-Risk Warnings

Contraindications & Red-Flag Precautions:
  • CRITICAL CONTRAINDICATIONS: (1) **Triptans (Sumatriptan/Rizatriptan)** are potent cranial AND coronary 5-HT1B vasoconstrictors — STRICTLY CONTRAINDICATED in **Ischaemic Heart Disease (angina, prior MI), Uncontrolled Hypertension, Prior Stroke/TIA, Peripheral Vascular Disease, Hemiplegic or Basilar Migraine, Severe Hepatic Impairment**, an

Key Clinical Precautions: High-alert hospital specialist agent; administer under close physiological and laboratory monitoring.

8. Adverse Effects Profile

Common & Mechanism-Related Adverse Effects:
  • Triptans: 'Triptan sensations' (transient non-ischaemic chest/neck/jaw tightness or warmth lasting 15–30 minutes in 5–10% — evaluate cardiac risk if severe!), tingling, flushing, dizziness, drowsiness
Serious / Dose-Limiting Adverse Effects:
  • Monitor for hemodynamic instability, organ toxicity, or severe hypersensitivity.

9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions

  • CRITICAL RIZATRIPTAN + PROPRANOLOL INTERACTION: Propranolol inhibits MAO-A metabolism of Rizatriptan and increases Rizatriptan plasma levels by **70%** -> when a migraine patient is taking Propranolol (Ciplar/Inderal) for prophylaxis, **Rizatriptan MUST be reduced to the 5 mg tablet (max 15 mg/24h)*

10. Clinical Monitoring, Patient Counselling & Storage

Clinical & Laboratory Monitoring: Continuous clinical, hemodynamic, and organ-function laboratory monitoring.

Pharmacist Patient Counselling Points:

  • FIVE VITAL COUNTER RULES: (1) Never take Suminat/Rizact and Vasograin (Ergotamine) within 24 hours of each other (causes dangerous blood vessel spasm and stroke/heart attack!), and never use Triptans if you have heart disease or uncontrolled high BP

Storage, Stability & Dispensing Safeguards: Store in original moisture-protected packaging below 25°C–30°C (or 2°C–8°C cold chain if parenteral/biological vial specified in strengths: Sumatriptan Tablets: 25 mg, 50 mg, 100 mg; Nasal Spray: 20 mg; SC: 6 mg. Rizatriptan Tablets/MD: 5 mg, 10 mg. Betahistine Tablets: 8 mg, 16 mg, 24 mg, 48 mg SR. Cinnarizine Tablets: 25 mg, 75 mg. Flunarizine Tablets: 5 mg, 10 mg). Missed-Dose Rule: Triptans: PRN; Flunarizine/Betahistine: Skip if missed

11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)

THE 12-STEP ORAL DRUG JOURNEY THROUGH THE HUMAN BODY (LADME) Note: IV bolus enters Step 6 directly (F = 100%); Sublingual & Transdermal routes bypass Step 4–5 Portal First-Pass Metabolism 1. Oral Administration • Tablet / Capsule swallowed • Gastric emptying to duodenum pH 1.5–3.5 (Stomach) 2. Disintegration & Dissolution • Tablet breaks into granules • API dissolves in GI fluid Noyes-Whitney Dissolution Rate 3. GI Epithelial Absorption • Crosses intestinal villi • Passive / Active / P-gp efflux Small Intestine (Large Surface Area) 4. Portal Circulation • Mesenteric veins → Portal vein • Delivers blood to liver sinusoids Pre-systemic Venous Conduit 5. First-Pass Metabolism • Gut & hepatic CYP450 extraction • High: GTN, Propranolol, Morphine Determines Bioavailability (F = f_a × (1-E_H)) 6. Systemic Circulation • Hepatic vein → IVC → Heart • Unbound vs Albumin-bound drug Only FREE drug is active 7–8. Tissue Distribution (Vd) • Capillary permeation to organs • Blood-Brain & Placental barriers Vd = Dose / C_0 (L or L/kg) 9. Target Site of Action • Receptors (GPCR, Ion channel) • Enzymes & Carrier Transporters Pharmacodynamic Effect (E_max, EC50) 10. Hepatic Biotransformation • Phase I (CYP450 Oxidation/Hydrolysis) • Phase II (Glucuronidation/Sulfation) Converts lipophilic drug → hydrophilic metabolite 11. Renal & Biliary Elimination • Nephron: Filtration + Secretion − Reabsorption • Biliary excretion & Enterohepatic recycling Total Clearance CL_tot = CL_renal + CL_hepatic 12. Excretion from the Body • Urine (Primary polar metabolite route) • Bile/Faeces, Expired Air, Sweat, Milk Elimination Half-Life t1/2 = (0.693 × Vd) / CL
svg-v339-01-adme-12-step-journey — 8.1 Complete 12-Step Journey of an Orally Administered Drug (ADME): Figure 8.1: The 12-step physiological journey of a typical orally administered solid dosage form through Liberation, Absorption, Distribution, Metabolism, and Excretion (LADME). Note: Parenteral (IV), sublingual, and inhalational routes bypass gastrointestinal absorption and/or hepatic first-pass metabolism.

12. Authoritative References, Regulatory Sources & Editorial Disclaimer

Primary Compendial & Guideline Reference: Indian Pharmacopoeia (IP 2022) • NFI • CDSCO • NCBI Bookshelf

Official Verification Portals: Indian Pharmacopoeia Commission (IPC) & National Formulary of India (NFI) • Central Drugs Standard Control Organization (CDSCO) • Ministry of Health & Family Welfare — NLEM 2022 • NCBI Bookshelf / StatPearls Pharmacology Reference • DailyMed (US FDA Official Prescribing Reference)

Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: VERIFIED_EDUCATIONAL_CONTENT

Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.